An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation in two upcoming investor conferences:
Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 a.m. EST
Jefferies London Healthcare Conference on November 16, 2021, at 5:40 p.m. GMT
Live webcasts of the presentations will be available on www.kalvista.com, with archives accessible for 30 days post-event. KalVista focuses on small molecule protease inhibitors for unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.
Positive
None.
Negative
None.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the following investor conferences:
Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 9:20 a.m. EST
Jefferies London Healthcare Conference on Tuesday, November 16, 2021 at 5:40 p.m. GMT
A live webcast of the presentations will be available on the Company’s website at www.kalvista.com. An archive of the presentations will be available on KalVista’s website for 30 days following the presentations.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.
What are the dates for KalVista Pharmaceuticals' upcoming investor conferences?
KalVista Pharmaceuticals will participate in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, and the Jefferies London Healthcare Conference on November 16, 2021.
What is the stock symbol for KalVista Pharmaceuticals?
The stock symbol for KalVista Pharmaceuticals is KALV.
Where can I watch the KalVista Pharmaceuticals presentations?
Live webcasts of the KalVista Pharmaceuticals presentations will be available on their website, www.kalvista.com.
What is KalVista Pharmaceuticals focused on?
KalVista Pharmaceuticals is focused on the discovery and development of small molecule protease inhibitors for diseases with significant unmet medical needs.
What therapies are KalVista Pharmaceuticals developing?
KalVista is developing KVD900 for acute hereditary angioedema attacks and KVD824 for prophylactic treatment of hereditary angioedema.
